ライフサイエンスコーパス: NPPV

1 NPPV as routine standard medical care resulted in the in

2 NPPV failure was associated with high hospital mortality

3 NPPV is successful in reversing acute respiratory failur

4 NPPV should be applied after careful discussion of the g

5 .52 intubations per 100 ICU days, p = 0.064, NPPV versus UMC, respectively).

6 can be classified into three categories: 1) NPPV as life support with no preset limitations on life-

7 5.63 intubations per 100 ICU days, p = 0.12, NPPV versus UMC, respectively).

8 imitations on life-sustaining treatments, 2) NPPV as life support when patients and families have dec

9 rsus 4.27 deaths per 100 ICU days, p = 0.21, NPPV versus UMC, respectively).

10 ed to forego endotracheal intubation, and 3) NPPV as a palliative measure when patients and families

11 aboratory data were collected for as long as NPPV was provided.

12 and each morning and evening for as long as NPPV was provided.

13 II and serum albumin level calculated before NPPV was predictive of hospital outcome.

14 In conclusion, NPPV with bilevel positive airway pressure reduces the r

15 regarding current sedation practices during NPPV.

16 ices and attitudes regarding sedation during NPPV.

17 ute hypoxemic respiratory failure who failed NPPV was 64%.

18 , we reviewed the rationale and evidence for NPPV, key points to communicate to patients and families

19 We hypothesized that PAV for NPPV would support gas exchange and avoid intubation as

20 ently use sedation and analgesic therapy for NPPV to treat acute respiratory failure, but practices v

21 esia, or hand restraints any of the time for NPPV patients, respectively, and the large majority repo

22 care settings, and alternative approaches if NPPV fails to achieve the original goals.

23 herefore, we innovated for them intermittent NPPV as a home treatment.

24 ere followed until discharge for duration of NPPV, survival status, and disposition.

25 owever, few data are available on the use of NPPV as routine standard medical care for patients with

26 is Task Force suggests an approach to use of NPPV for patients and families who choose to forego endo

27 eveloping an approach for considering use of NPPV for patients who choose to forego endotracheal intu

28 The use of NPPV for patients with acute respiratory failure can be

29 respiratory symptoms improved by the use of NPPV in children with acute severe asthma with respirato

30 s with acute respiratory failure, the use of NPPV in patients who have decided to forego endotracheal

31 patients, families, and clinicians on use of NPPV in these contexts.

32 ng DNI patients and their families on use of NPPV.

33 Patients were begun on NPPV with mean inspiratory and expiratory pressures of 1

34 We reviewed English-language literature on NPPV for acute respiratory failure.

35 ory insufficiency were randomized to receive NPPV with PAV delivered using the Respironics Vision ven

36 All patients receiving NPPV for a 1-yr period for acute or acute on chronic res

37 All patients receiving NPPV for acute respiratory failure were screened and enr

38 ETI was lower among COPD patients receiving NPPV, this trend did not reach statistical significance

39 diction of outcome in DNI patients receiving NPPV.

40 These results suggest that NPPV may be a useful treatment option for patients with

41 ry volume in 1 second in all cases after the NPPV therapy, while V50 and V25 were improved.

42 Thirty-two patients were evaluated in the NPPV group and 29 in the UMC group.

43 Patients with hypoxemic ARF in the NPPV group had a significantly lower ETI rate than those

44 ubation (ETI) was significantly lower in the NPPV than in the UMC group (6.38 intubations versus 21.2

45 ntubation can be avoided by the start of the NPPV.

46 postextubation), and were then randomized to NPPV or UMC.

47 We tried to use NPPV for 30 minutes in our clinic, and their symptoms im

48 d to evaluate the clinical outcomes of using NPPV for patients who choose to forego endotracheal intu

49 Noninvasive positive-pressure ventilation (NPPV) has been shown to be effective in select patients

50 h noninvasive positive pressure ventilation (NPPV) is a widely accepted treatment for some patients w

51 Noninvasive positive-pressure ventilation (NPPV) is increasingly used in patients with acute respir

52 Noninvasive positive pressure ventilation (NPPV) is usually applied using pressure support ventilat

53 d noninvasive positive pressure ventilation (NPPV) with a helmet-type mask in two young children with

54 d noninvasive positive-pressure ventilation (NPPV), using bilevel positive airway pressure, with usua

55 t noninvasive positive pressure ventilation (NPPV).

56 p < .001) were the variables associated with NPPV failure.

57 n-COPD category had a lower rate of ETI with NPPV than with UMC (8.45 intubations versus 30.30 intuba

58 igh overall mortality rate when treated with NPPV, but those with diagnoses such as congestive heart